Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Vivodyne logo — We accelerate the discovery of cures to human diseases with...

Vivodyne

We accelerate the discovery of cures to human diseases with ultra-scalable drug testing on lab-grown human tissues.

Founded 2020 United States Philadelphia, United States 40 employees Seed Total: $40.00M Biotechnology, Lifestyle

General Information

Company Name Vivodyne
Founded Year 2020
Location United States Philadelphia, United States +2
Employees 40
Industries Biotechnology, Lifestyle
Funding Stage Seed
Social

Get notified when Vivodyne moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

In The News Aug 22, 2026

Featured on Thenextweb: This startup is training an AI model on skin that stays alive for a month

Get alerts when Vivodyne shows new signals

AI Insight

Bounce Watch AI
2 months ago

Vivodyne recently secured a significant $38 million Seed round in November 2023, building on an earlier $2 million Seed in 2021. This substantial capital injection, backed by prominent investors like Khosla Ventures, signals strong validation of their AI-powered, robotic platform for drug testing on lab-grown human tissues. The funding positions Vivodyne for accelerated growth in R&D, operational scaling, and expanding its biopharma partnerships, further cementing its role in ethical preclinical testing.

Signal Types
Funding
Strategic Labels
Growth Capital Market Validation R&D Acceleration
Next Move: Hiring
·
Impact: 9/10
·
Ideal For: AI Biopharma VCs — Early-Stage Growth

About Vivodyne

Vivodyne, founded in 2020, is a cutting-edge player in the Biotechnology and Lifestyle industries. Their motto, "We accelerate the discovery of cures to human diseases with ultra-scalable drug testing on lab-grown human tissues," succinctly captures their mission to revolutionize drug discovery processes.

This United States-based startup is at the forefront of utilizing lab-grown 3D human tissues for scalable drug testing, potentially transforming how treatments for human diseases are discovered and developed. Its technology promises to expedite the drug discovery timeline significantly, targeting a critical bottleneck in medical research.

Vivodyne recently secured a significant financial backing of $38.00M in a Seed Round on 22 November 2023. This investment round attracted notable investors, including Khosla Ventures, Kairos Ventures, Bison Ventures, MBX Capital, and CS Venture Opportunities Fund. Their involvement underscores confidence in Vivodyne's innovative approach and growth potential.

Taxonomy: drug discovery, robotic systems, cellular therapies, lab-grown tissues, automated technology, disease cures, 3D tissue culturing, drug testing, human health, biomedical research

Services & Products

Development of lab-grown human organ models
AI-driven drug discovery and testing
Automation of massive-scale human tissue studies
Provision of preclinical human data for new therapies

Target Customers

Biopharma companies Pharmaceutical researchers Drug developers Healthcare innovation sectors

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 5
Investor Investor Investor Investor
•••• •••• 		22 Nov 2023
Seed Round •••••• 1
Investor
11 Mar 2021

Latest News

View All
This startup is training an AI model on skin that stays alive for a month — Thenextweb
This startup is training an AI model on skin that stays alive for a month
Thenextweb Aug 22, 2026

Vivodyne Alternatives & Competitors

View All Alternatives
Vivodyne vs
Infinimmune
Infinimmune United States

Treating human disease with truly human therapeutics.

Seed
16 employees
Biotechnology, Health Care
Compare Vivodyne vs Infinimmune
Vivodyne vs
Curi Bio
Curi Bio United States

Human Data for Next Generation Medicines

Grant
59 employees
AI, Biopharma
Compare Vivodyne vs Curi Bio
Vivodyne vs
OrganOmics
OrganOmics United States

Human Tissues for Human Therapeutics

Non Equity Assistance
2 employees
Biotechnology, Health Care
Compare Vivodyne vs OrganOmics
View all alternatives

FAQ About Vivodyne

We accelerate the discovery of cures to human diseases with ultra-scalable drug testing on lab-grown human tissues.
Vivodyne was founded in 2020.
Vivodyne is headquartered in Philadelphia, United States.
Vivodyne operates in the following industries: Biotechnology, Lifestyle.
Vivodyne has approximately 40 employees.
Vivodyne has completed 2 funding rounds, raising a total of $40.00M. The latest funding stage is Seed.
Vivodyne offers: Development of lab-grown human organ models, AI-driven drug discovery and testing, Automation of massive-scale human tissue studies, Provision of preclinical human data for new therapies.
Top alternatives and competitors to Vivodyne include Infinimmune, Curi Bio, OrganOmics, TRIANNI, Inc an AbCellera Company, AnaBios Corporation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vivodyne and Infinimmune are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Vivodyne and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy